loading...| Preferred Name | suramin sodium | |
| Synonyms |
Germanin sodium suramin Naganol Fourneau 309 Moranyl 309 F 8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid hexasodium Salt Naganin CI-1003 Belganyl Naphuride suramin hexasodium Antrypol Naganinum |
|
| Definitions |
A sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1848" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1848" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000040052 |
|
| altLabel |
Germanin sodium suramin Naganol Fourneau 309 Moranyl 309 F 8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid hexasodium Salt Naganin CI-1003 Belganyl Naphuride suramin hexasodium Antrypol Naganinum |
|
| CAS Registry |
129-46-4 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000041483 http://purl.bioontology.org/ontology/PDQ/CDR0000041292 http://purl.bioontology.org/ontology/PDQ/CDR0000041435 http://purl.bioontology.org/ontology/PDQ/CDR0000041482 http://purl.bioontology.org/ontology/PDQ/CDR0000041436 http://purl.bioontology.org/ontology/PDQ/CDR0000322263 http://purl.bioontology.org/ontology/PDQ/CDR0000038158 http://purl.bioontology.org/ontology/PDQ/CDR0000271142 http://purl.bioontology.org/ontology/PDQ/CDR0000322262 http://purl.bioontology.org/ontology/PDQ/CDR0000041752 http://purl.bioontology.org/ontology/PDQ/CDR0000042084 http://purl.bioontology.org/ontology/PDQ/CDR0000041775 http://purl.bioontology.org/ontology/PDQ/CDR0000040262 |
|
| cui |
C1515086 C0878165 C0242512 C0878167 C1527097 C0813205 C0878166 C0878169 C0878171 C1515085 C0878168 |
|
| Date last modified |
2017-11-03 |
|
| definition |
A sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1848" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1848" NCI Thesaurus) |
|
| Legacy PDQ ID |
2791 |
|
| LT |
TRD |
|
| NCI ID |
C1848 |
|
| notation |
CDR0000040052 |
|
| NSC Code |
34936 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
suramin sodium |
|
| tui |
T109 T121 |